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TLF and revascularization rates with favorable safety outcomes for
the treatment of small vessels and long lesions through 5 years.
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BACKGROUND Recent study reported that arterial healing of drug
eluting stents was impaired with greater delay at the ﬂow divider
(high shear stress region) as compared with the opposite side of side
branch (SB) (low shear stress region). This study investigated the
differences in neointimal growth on stent struts between thin- and
thick-strut drug eluting stents (DES) implanted in coronary bifurca-
tion lesions by using optical coherence tomography (OCT).
METHODS Sixty-two bifurcation lesions treated with second genera-
tion DES were evaluated with OCT in 51 patients (66.1 y.o) at 6 to 12
months follow-up angiography. The stent strut was deﬁned as thin
when less than 100mm and thick when more than 100mm. Each lesions
were divided into thick-DES (n¼20; Nobori biolimus-eluting stents) or
thin-DES (n¼42; Xience everolimus-eluting stents and Resolute
Integrity zotarolimus-eluting stents). Neointimal coverage was
assessed based on cross-sectional OCT images containing SB at 400mm
interval, and separately evaluated according to three independent
regions: SB ostium (SO), the 1/2 circumference of the vessel wall
opposite to SB (LS; low share stress region), and the vessel wall
adjacent to SB (HS; high shear stress region). Incidence of uncovered
struts and neointimal thickness were measured on the cross sectional
OCT images.
RESULTS Total of 2437 struts were analyzed in this study (thick-DES:
911 vs. thin-DES: 1526). The incidence of uncovered struts was
signiﬁcantly higher at HS region compared with LS regions in thick-
DES (16.8% vs. 7.9%, p<0.01), while there was no signiﬁcant differ-
ence in thin-DES at both HS and LS region (7.3% vs. 5.4%, p¼0.1643).
The incidence of uncovered struts was signiﬁcantly higher in thick-
DES compared with thin-DES at HS region (16.8% vs 7.3%, p<0.01),
while there was no signiﬁcant difference at both LS and SO region
(7.9% vs. 5.4%, p¼0.0846; 34.7% vs. 36.4%, p¼0.7606, respectively).
Neointimal thickness was signiﬁcantly smaller in thick-DES compared
with thin-DES at both HS and LS region (69.446.6mm vs.
99.970.8mm, p<0.01; 72.247.6mm vs. 98.569.5mm, p<0.01,
respectively), while there was no signiﬁcant difference at SO region
(48.731.8mm vs. 48.736.1mm, p¼0.8386).
CONCLUSIONS Thin strut DES was homogeneously endothelialized in
bifurcation lesions and may have more favorable arterial healing
response for bifurcation lesions compared with thick strut DES.
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BACKGROUND Chronic total occlusions (CTO), deﬁned by TIMI 0 ﬂow
and duration of occlusion of more than 3 month, are associated with a
higher risk of restenosis compared to other lesion types. We evaluated
clinical and angiographic results after recanalization of CTOs with the
Sirolimus eluting Orsiro hybrid stent with bioresorbable polymer
coating. Orsiro is a cobalt chromium stent with an absorbable polymer
and thin struts of 60 mm. We compared two consecutive patient series
undergoing recanalization for CTO with either the Orsiro Sirolimus-
eluting stent (O-SES) or a Zotarolimus- eluting stent (ZES)
METHODS 74 patients after successful recanalization of a true CTO in
a native coronary artery where enrolled in our prospective registry
(clinical trials.gov NCT02162082) and compared with 57 patients
treated with a Zotarolimus-eluting stent. In 68 % vs 50% CTO recan-
alization was performed by antegrade and in 32%vs 5% by retrograde
approach. After pre-dilatation a mean of 2.71.3 (range 1-6) Orsiro
stents and 2.71.2 (1-7) ZES were implanted with a mean length of
81.930.6mm. 32.4% (N¼ 24/74) of patients in the Orsiro group suf-
fered from diabetes mellitus and 28.1%(N¼16/57)in the Zotarolimus
group. In 66.2% vs 61.4% CTO was located in RCA, 18.9%vs15.8% in
LCX and in 14.9%vs 22.8% in LAD. Reference diameter post PCI was
3.040.49mm (3.190.56mm), MLD 2.820.51mm (3.060.48mm)
and percent diameter stenosis 7.610.0 (3.78.3). Dual antiplatelet
therapy (DAPT) was recommended for 12 months with aspirin and
clopidogrel. Control angiography was scheduled after 9 and clinical
follow-up after 12 month. The primary angiographic outcome was in-
stent late lumen loss. Secondary angiographic endpoints include
minimal luminal diameter, percentage of diameter stenosis, binary
restenosis. Primary clinical outcome measures were target lesion
revascularization rate (TLR) and major adverse cardiac events (MACE)
deﬁned as composite of cardiac death, myocardial infarction related
to the target vessel and target vessel revascularization.
RESULTS The primary endpoint in-stent late lumen loss was
0.240.53mm for the Orsiro stent compared with 0.590.72mm for
the Zotarolimus stent (p¼0.01), MLD was 1.990.63mm versus
1.870.80mm (p¼0.86), percent diameter stenosis 24.719.2% vs.
27.728.7% (p¼0.58), respectively. TLR was 9.7% for O-SES and 10.5 %
for ZES, resulting in a total MACE rate of 10.8% vs 12.3% (p¼0.79). Of
note, there was no deﬁnite or probable stent thrombosis according to
ARC criteria in both groups within 12 months DAPT treatment.
CONCLUSIONS Treatment of true CTO lesions with the Sirolimus
eluting abluminal coated Orsiro stent resulted in a signiﬁcantly lower
in-stent late lumen loss compared with Zotarolimus eluting stents and
no occurrence of deﬁnite or probable stent thrombosis with a 12
months dual antiplatelet therapy. Clinical results were similar to
Zotarolimus eluting stents.
CATEGORIES CORONARY: Stents: Drug-Eluting
KEYWORDS Chronic total occlusion, Drug-eluting stent, sirolimus
TCT-564
Clinical Predictors of Target Lesion Revascularization after SES or EES
implantation
Seiichi Hiramori,1 Hirotoshi Watanabe,2 Hiroki Shiomi,3 Ken Kozuma,4
Takeshi Morimoto,5 Keiichi Igarashi,6 Kazushige Kadota,7
Kengo Tanabe,8 Yoshihiro Morino,9 Shinichi Shirai,10 Kenji Ando,11
Masakiyo Nobuyoshi,1 Takeshi Kimura12
1Kokura Memorial Hospital, Kitakyushu, Japan; 2Kyoto University
Graduate School of Medicine, Kyoto, Japan; 3Kyoto University
Graduate School of Medicine, Kyoto, NA; 4Teikyo University Hospital,
Tokyo, Japan; 5Hyogo College of Medicine, Nishinomiya, Hyogo;
6Japan Community Health care Organization Hokkaido Hospital,
Sapporo, Japan; 7Kurashiki Central Hospital, Kurashiki, Japan; 8Mitsui
Memorial Hospital, Tokyo, Japan; 9Iwate Medical University, Morioka,
Iwate; 10Kokura Memorial Hospiral, Kitakyushu, Fukuoka; 11Kokura
memorial hospital, Kitakyusyu, Japan; 12Kyoto University, Kyoto,
Japan
BACKGROUND Several studies have performed the comparison of
outcomes between 1st generation drug eluting stent Sirolimus-Eluting
Stent (SES) and 2nd generation drug eluting stent Everolimus-Eluting
